pISSN 1226-6051
eISSN 2508-786X

Table. 1.

Table. 1.

Baseline characteristics of users of rivaroxaban vs. warfarin

Characteristics, % Before PS matched 1:1 PS matched


Rivaroxaban (n=1,079) Warfarin (n=2,401) p-value Rivaroxaban (n=1,079) Warfarin (n=1,079) p-value
Age, years 75.86±6.31 74.80±6.17 <0.01 75.86±6.31 75.53±6.07 0.22
Age ≥ 75 years 55.61 48.31 <0.01 55.61 56.26 0.80
Female 52.64 47.31 <0.01 52.64 52.55 1.00
Comorbidity
Hypertension 79.43 74.05 <0.01 79.43 79.33 1.00
Diabetes 18.44 15.12 0.02 18.44 17.24 0.50
Myocardial infarction 1.48 2.17 0.19 1.48 1.67 0.86
Heart Failure 43.28 34.07 <0.01 43.28 42.17 0.63
Ischemic stroke/Transient ischemic attack 0.28 0.04 0.09 0.28 0 0.25
Peripheral vascular disease 0.74 1.46 0.10 0.74 1.30 0.28
Dementia 0.46 0.54 1.00 0.46 0.56 1.00
Renal Disease 1.30 3.17 <0.01 1.30 1.20 1.00
Chronic pulmonary disease 6.58 7.91 0.19 6.58 8.90 0.05
Liver disease 5.56 5.29 0.75 5.56 4.91 0.56
Cancer 1.20 1.00 0.59 1.20 1.11 1.00
depression 1.85 2.46 0.33 1.85 2.32 0.55
Hematological disorders (Coagulopathy, anemia) 2.87 5.83 <0.01 2.87 2.41 0.59
Alcoholism 0.19 0.58 0.17 0.19 0.37 0.69
GI bleeding 0.46 0.33 0.56 0.46 0.09 0.22
Other bleeding 0.74 1.25 0.22 0.74 0.46 0.58
CHA2DS2-VASC score ≥ 2 98.61 94.63 <0.01 98.61 98.52 1.00
Medications,%
Digoxin 19.74 21.53 0.24 19.74 21.59 0.31
Clopidogrel 4.91 5.08 0.87 4.91 5.10 0.92
Antiplatelets 8.53 13.33 <0.01 8.53 8.06 0.76
ACEI/ARB 37.81 36.44 0.45 37.81 38.09 0.93
β-blockers 47.08 41.90 <0.01 47.08 48.19 0.63
Ca channel blockers 9.36 9.95 0.62 9.36 10.75 0.32
Anti-arrhythmias 18.44 16.41 0.14 18.44 18.91 0.83
Statins 30.58 28.65 0.26 30.58 29.56 0.64
Diabetes medication 8.99 9.12 0.95 8.99 10.01 0.46

PS, propensity score

Korean J Clin Pharm 2022;32:37-46 https://doi.org/10.24304/kjcp.2022.32.1.37
© 2022 Korean J Clin Pharm